3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
29
NETWORK
4
NIH
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
14
Lymphoma, Non-Hodgkin
12
Leukemia, Myeloid, Acute
12
Leukemia
5
Hodgkin Disease
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Chemotherapy-induced Neutropenia
3
Breast Neoplasms
3
Small Cell Lung Carcinoma
2
Plasmacytoma
2
Paraproteinemias
2
Neutropenia
2
Neoplasm Metastasis
2
Leukemia, Plasma Cell
2
Chemotherapy Induced Neutropenia
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Histologic Type
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Rituximab
101
Cyclophosphamide
51
Prednisone
32
Doxorubicin
32
Vincristine
31
Gemcitabine
29
Lenalidomide
27
Oxaliplatin
22
Bendamustine Hydrochloride
19
ibrutinib
16
fludarabine
16
tafasitamab
12
polatuzumab vedotin
12
venetoclax
11
tisagenlecleucel
11
obinutuzumab
11
loncastuximab tesirine
9
Etoposide
9
zanubrutinib
8
Prednisolone
8
Injections
8
Ifosfamide
8
Carboplatin
8
selinexor
7
pembrolizumab
7
durvalumab
7
axicabtagene ciloleucel
7
Dexamethasone
7
tazemetostat
6
parsaclisib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Large B-Cell, Diffuse
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT05139017
2026-06-04
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
290 enrolled